The effect of salmon calcitonin on bone mineral density and calcium-phosphate metabolism in chronic hemodialysis patients with secondar hyperparathyroidism;Wpływ łososiowej kalcytoniny na gȩstość mineralna̧ kości oraz metabolizm wapnia i fosforu u chorych z wtórna̧ nadczynnościa̧ przytarczyc przewlekle hemodializowanych

Polskie Archiwum Medycyny Wewnetrznej

Volumn 112, Issue 1, 2004, Pages 797-803

  Matuszkiewicz Rowińska, Joanna ^a   Niemczyk, Stanisław ^b   Przedlacki, Jerzy ^a   Puka, Janusz ^c   Świtalski, Marek ^d   Ostrowski, Kazimierz ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

^b Oddzial Wewnetrzny ze Stacja Dializ   (Poland)

^c Osrodek Dializ Hospital Praskiego

^d Oddzial Nefrologii Hospital W   (Poland)

Author keywords

Bone densitometry; Bone mineral density; Chronic renal failure; Hemodialysis; Parathormon; Salmon calcitonin; Secondary hyperparathyroidism

Indexed keywords

ALUMINUM HYDROXIDE; CALCITONIN; CALCIUM; CALCIUM CARBONATE; HYDROXYPROLINE; PARATHYROID HORMONE; PHOSPHATE; SALCATONIN;

ADULT; ARTICLE; BONE DENSITY; BONE MINERAL; CALCIUM BLOOD LEVEL; CALCIUM METABOLISM; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; DIALYSATE LEVEL; DIET SUPPLEMENTATION; DRUG EFFECT; DUAL ENERGY X RAY ABSORPTIOMETRY; HEMODIALYSIS; HUMAN; OSTEOLYSIS; PARATHYROID FUNCTION; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; PHOSPHATE METABOLISM; SECONDARY HYPERPARATHYROIDISM; THYROID PARAFOLLICULAR CELL; UREMIA;

EID: 4043106223     PISSN: 00323772     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Llach F., Bover J.: Renal osteodystrophy. [w:] The Kidney, (red.). Brenner B.M., W.B. Saunders Company, Philadeplphia, 1996, 2187.
2. Schaefer K.: Unsatisfactory control of serum phosphate: why is it so common and what can be done? Nephrol. Dial. Tranplant., 1994, 10, 1366.
3. Finch J., Brown A., Kubodera N., Nishii Y., Slatopolsky E.: Different effects of 1,25(OH)2D3 and 22-oxacalcitriol on phosphate and calcium metabolism. Kidney Int., 1993, 42, 561.
4. Heynen G., Kanis J.A., Oliver D.O., Earnshaw M.: Evidence that endogenous calcitonin protects against renal bone disease. Lancet, 1976, 2, 1322.
5. Chambers T.J., Moore A.: The sensitivity of isolated osteoclasts to morphological transformation by calcitonin. J. Clin. Endocrinol. Metab., 1983, 57, 819.
6. Fairley J.R., Tarbaux N.M., Hall S.L., Linkhart T.A., Baylink D.J.: The anti-bone resorptive agent calcitonin also acts in vitro to directly increase bone formation and bone cell proliferation. Endocrinology, 1998, 123, 159.
7. Austin L.A., Heath III H.: Calcitonin: Physiology and patophysiology. N. Engl. J. Med., 1981, 304, 269.
8. Azria M.: Endogenous calcitonin. [w:] Azria M.: The calcitonins. Basel, Karger, 1989.
9. Talmage R. V., Vanderwiel C.J., Matthews J.L.: Calcitonin and phosphate. Mol. Cell. Endocrinol., 1981, 24, 235.
10. Rodriguez M., Felsenfeld A.J., Torres A., Pederson L., Llach F.: Calcitonin, an important factor in the calcemic response to parathyroid hormone in the rat. Kidney Int., 1991, 40, 219.
11. Malluche H.H., Faugere M.C.: Renal bone disease 1990: An unmet challenge for the nephrologist. Kidney Int., 1990, 38, 193.
12. Canalis E., McCarthy T.L., Centrella M.: Production, regulation and effects of bone growth factors, [w:] Christiansen C., Overgaard K.: Osteoporosis 90, Third Int. Symp. On Osteoporosis, Copehagen 1990, 243.
13. Gennari C., Montagnani M., Nardi P., Zacchei F., Bigazzi S., Cepollaro C.: Long-term effect of cyclic or continuous calcitonin treatment on bone mass in established postmenopausal osteoporosis. [w:] Christiansen C., Jahansen J.S., Riis B.J.: Osteoporosis 1987. Viborg, Norhaven.
14. Civitelli R., Gonelli S., Zacchei F. i wsp.: Bone turnover in postmenopausal osteoporosis: Effect of calcitonin treatment. J. Clin. Invest., 1988, 82, 1268.
15. Gennari C.: Zastosowanie kalcytoniny łososiowej w profilaktyce i leczeniu osteoporozy. Post. Nauk. Med., 1990, III, 165.
16. Fornaiser V.L., Stapleton K., Williams C.C.: Histologic changes in Paget's disease treated with calcitonin. Human Pathology 1978, 9, 455.
17. Muff R., Dambacher M.A., Perrenoud A., Simon C., Fischer J.A.: Efficacy of intranasal human calcitonin in patients with Paget's disease refractory to salmon calcitonin. Am. J. Med., 1990, 89, 181.
18. Cundy T., Kanis J.A., Heynen G., Paton S., Earnshaw M., Woods C.G.: Deterioration of renal bone disease in patients treated with salmon calcitonin. Cin. Endocrinol., 1982, 16, 29.
19. Nordal K.P., Halse J., Dahl E.: The effect of nasal calcitonin on bone mineral density in renal transplant recipients. Nephrol. Dial. Tranplant., 1996, 11, 1212.
20. Ionova D., Zlatarska S., Kirjakow Z:. Is calcitonin a helper of phosphate binders in the control of renal osteodystrophy? Nephrol. Dial. Transplant. 1995, 10, 1782.
21. Martinez M.E., Miguel J.L., Gomez P. i wsp.: Plasma calcitonin concentration in patients treated with chronic dialysis: differences between hemodialysis and CAPD. Clin. Nephrol., 1983, 19, 250.
22. Furlong T., Chan Y.L., Cornish C., McDowall D., Mahony J., Clifton-Bligh P.: Immunoreactive serum calcitonin and skeletal histology in chronic renal failure. Nephron 1991, 58, 138.
23. Torres A., Rodriguez M., Felsenfeld A., Martin-Malo A., Llach F.: Sigmoidal relationship between calcitonin and calcium: studies normal, parathyroidectomied and azotemic rats. Kidney Int., 1991, 40, 700.
24. Simmons R.E., Hjelle J.T., Mahoney C. i wsp.: Renal metabolism of calcitonin. Am. J. Physiol., 1998, 23, 593.
25. Messa P., Mioni G., Turrin D., Guerra U.P.: The calcitonin-calcium relation curve and calcitonin secretory parameters in renal patients with variable degrees of renal function. Nephrol. Dial. Transplant, 1995, 10, 2259.